IDEAS home Printed from https://ideas.repec.org/h/spr/sprchp/978-3-319-09075-7_1.html
   My bibliography  Save this book chapter

Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development

In: Optimization of Pharmaceutical R&D Programs and Portfolios

Author

Listed:
  • Zoran Antonijevic

    (Cytel Inc.)

Abstract

In drug development decisions regarding various development options should be defined such that that the expected value of a product or a portfolio is maximized. This needs to be done through the process of quantitative optimization of development decisions. This process involves development of multiple scenarios that are best compared by using simulations. While this optimization could focus on individual development programs, it is preferable that these decisions are made at the portfolio level, as individual programs are interdependent. The value of a product depends on quality of product itself, and quality of development program. The value of a portfolio depends on the value of individual products and the strategy for portfolio optimization. Key concepts that are addressed here are: 1. Drug development decisions should be made at the portfolio level. Budgets are limited and are determined at the portfolio level; therefore decisions within individual programs should be interrelated. 2. Study design and development strategy have a major impact on the success of drug development at: Trial level by application of adaptive design. Program level. More effective dose-finding leads to higher success rates in Phase 3 and an improved efficacy/safety profile Portfolio level. Improved allocation of a fixed budget into individual trials leads to an improved value of the portfolio. 3. An integrated, R&D and commercial approach is necessary for optimizing pharmaceutical portfolios.

Suggested Citation

  • Zoran Antonijevic, 2015. "Need for Optimal Design of Pharmaceutical Programs and Portfolios in Modern Medical Product Development," Springer Books, in: Zoran Antonijevic (ed.), Optimization of Pharmaceutical R&D Programs and Portfolios, edition 127, chapter 0, pages 3-16, Springer.
    • Handle: RePEc:spr:sprchp:978-3-319-09075-7_1
    DOI: 10.1007/978-3-319-09075-7_1
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Stig Johan Wiklund, 2019. "A modelling framework for improved design and decision-making in drug development," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-22, August.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:sprchp:978-3-319-09075-7_1. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.